Here are five findings:
1. The findings revealed the presence or absence of dueling toxins explains the different between HA-MRSA and its less virulent cousin, CA-MRSA.
2. A key toxin, LUK-PC, counteracts the affects of a more deadly toxin, LUK-ED, which is secreted by both forms of MRSA.
3. The competing relationship between the two bacterial toxin accounts for why MRSA is more widespread and less fatal than hospital-acquired MRSA.
4. Researchers can now take a broader view of the pathogen, which will help them target more than one toxin to develop an effective vaccine.
5. The next step entails analyzing the biological mechanisms by which LUK-PV and LUK-ED target, attach and destroy white and red blood cell, thus making the host more susceptible to infection.
More articles on quality & infection control:
NC reports 1st death from West Nile in 2015 — 4 quick facts
Haldor Advanced’s sponge system to improve patient safety: 5 things to know
Feeling sick? — Google may know what’s bringing you down
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.